{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T05:26:37Z","timestamp":1730870797177,"version":"3.28.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,5]]},"DOI":"10.7759\/cureus.73049","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:02:58Z","timestamp":1730811778000},"source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab-Induced Insulin-Dependent Diabetes Mellitus in a Patient With Triple-Negative Breast Cancer: A Rare Immune-Related Adverse Event"],"prefix":"10.7759","author":[{"given":"Mirac Burak","family":"Tak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaid","family":"Munir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1110","article-title":"FDA approval summary: pembrolizumab for neoadjuvant and adjuvant treatment of patients with high-risk early-stage triple-negative breast cancer","volume":"28","author":"Shah M","year":"2022","unstructured":"Shah M, Osgood CL, Amatya AK, et al.. FDA approval summary: pembrolizumab for neoadjuvant and adjuvant treatment of patients with high-risk early-stage triple-negative breast cancer. Clin Cancer Res. 2022, 28:5249-53. 10.1158\/1078-0432.CCR-22-1110","journal-title":"Clin Cancer Res"},{"key":"ref2","unstructured":"Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer. (2022). Accessed. October 24, 2024: https:\/\/www.nice.org.uk\/guidance\/ta851\/chapter\/1-Recommendations."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.24479","article-title":"New-onset autoimmune diabetes mellitus presenting as diabetic ketoacidosis in association with pembrolizumab therapy and long term follow-up: case report","volume":"14","author":"Pachpande V","year":"2022","unstructured":"Pachpande V, Mullangi S, Lekkala MR, Patel A. New-onset autoimmune diabetes mellitus presenting as diabetic ketoacidosis in association with pembrolizumab therapy and long term follow-up: case report. Cureus. 2022, 14:e24479. 10.7759\/cureus.24479","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2023.0072","article-title":"Immune-checkpoint inhibitors-induced type 1 diabetes mellitus: from its molecular mechanisms to clinical practice","volume":"47","author":"Cho YK","year":"2023","unstructured":"Cho YK, Jung CH. Immune-checkpoint inhibitors-induced type 1 diabetes mellitus: from its molecular mechanisms to clinical practice. Diabetes Metab J. 2023, 47:757-66. 10.4093\/dmj.2023.0072","journal-title":"Diabetes Metab J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/0891060310002276","article-title":"Diabetes mellitus following cisplatin treatment","volume":"42","author":"Nan DN","year":"2003","unstructured":"Nan DN, Fern\u00e1ndez-Ayala M, Vega Villegas ME, Garcia-Casta\u00f1o A, Rivera F, Lopez-Brea M, Gonz\u00e1lez-Mac\u00edas J. Diabetes mellitus following cisplatin treatment. Acta Oncol. 2003, 42:75-8. 10.1080\/0891060310002276","journal-title":"Acta Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcma.2018.05.008","article-title":"Hyperglycemia crisis in head and neck cancer patients with platinum-based chemotherapy","volume":"81","author":"Huang CY","year":"2018","unstructured":"Huang CY, Lin YS, Liu YH, Lin SC, Kang BH. Hyperglycemia crisis in head and neck cancer patients with platinum-based chemotherapy. J Chin Med Assoc. 2018, 81:1060-4. 10.1016\/j.jcma.2018.05.008","journal-title":"J Chin Med Assoc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-245846","article-title":"Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab","volume":"15","author":"Zand Irani A","year":"2022","unstructured":"Zand Irani A, Almuwais A, Gibbons H. Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab. BMJ Case Rep. 2022, 15:10.1136\/bcr-2021-245846","journal-title":"BMJ Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v15.i5.576","article-title":"Pembrolizumab autoimmune related diabetes: moving forward, keep learning","volume":"15","author":"Garcia JA","year":"2024","unstructured":"Garcia JA, Alcaraz D, Holgado E, Cou\u00f1ago F. Pembrolizumab autoimmune related diabetes: moving forward, keep learning. World J Clin Oncol. 2024, 15:576-9. 10.5306\/wjco.v15.i5.576","journal-title":"World J Clin Oncol"},{"key":"ref9","article-title":"Immune checkpoint inhibitors-associated diabetes and ketoacidosis were found in FDA adverse event reporting system: a real-world evidence database study","volume":"30","author":"Han M","year":"2024","unstructured":"Han M, Jiang L, Zhao B, Liu X, Yang C, Chen W. Immune checkpoint inhibitors-associated diabetes and ketoacidosis were found in FDA adverse event reporting system: a real-world evidence database study. Endocr Pract. 2024, 30:887-92.","journal-title":"Endocr Pract"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"24","author":"Stamatouli AM","year":"2018","unstructured":"Stamatouli AM, Quandt Z, Perdigoto AL, et al.. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018, 24:1471-80. 10.2337\/dbi18-0002","journal-title":"Diabetes"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen JB","year":"2017","unstructured":"Haanen JB, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017, 28:iv119-42. 10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14636","article-title":"A guideline for the outpatient management of glycaemic control in people with cancer","volume":"39","author":"Joharatnam-Hogan N","year":"2022","unstructured":"Joharatnam-Hogan N, Chambers P, Dhatariya K, Board R. A guideline for the outpatient management of glycaemic control in people with cancer. Diabet Med. 2022, 39:e14636. 10.1111\/dme.14636","journal-title":"Diabet Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-217454","article-title":"Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma","volume":"2016","author":"Aleksova J","year":"2016","unstructured":"Aleksova J, Lau PK, Soldatos G, McArthur G. Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. BMJ Case Rep. 2016, 2016:10.1136\/bcr-2016-217454","journal-title":"BMJ Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241241493","article-title":"Pembrolizumab induced type 1 diabetes mellitus in a patient with metastatic melanoma and literature review on steroids as a treatment option","volume":"30","author":"Greene A","year":"2024","unstructured":"Greene A, Penner S, Kunesh J, Altaf A, McGrade W, Niu J. Pembrolizumab induced type 1 diabetes mellitus in a patient with metastatic melanoma and literature review on steroids as a treatment option. J Oncol Pharm Pract. 2024, 30:1084-8. 10.1177\/10781552241241493","journal-title":"J Oncol Pharm Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/314845-pembrolizumab-induced-insulin-dependent-diabetes-mellitus-in-a-patient-with-triple-negative-breast-cancer-a-rare-immune-related-adverse-event","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:03:01Z","timestamp":1730811781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/314845-pembrolizumab-induced-insulin-dependent-diabetes-mellitus-in-a-patient-with-triple-negative-breast-cancer-a-rare-immune-related-adverse-event"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.73049","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,5]]}}}